Background. The Food and Drug Administration (FDA) has received reports of
depression and suicide in patients treated with isotretinoin.
Objective: Our purpose was to provide the number and describe the cases of
depression and suicide reported to the FDA in US patients treated with isot
retinoin and to consider the nature of a possible association between isotr
etinoin and depression,
Methods: An analysis was made of reports of depression, suicidal ideation,
suicide attempt, and suicide in US isotretinoin users voluntarily submitted
to the manufacturer and the FDA from 1982 to May 2000 and entered in the F
DAs Adverse Event Reporting System database.
Results. From marketing of isotretinoin in 1982 to May 2000, the FDA receiv
ed reports of 37 US patients treated with isotretinoin who committed suicid
e; 110 who were hospitalized for depression, suicidal ideation, or suicide
attempt; and 284 with nonhospitalized depression, for a total of 431 patien
ts. Factors suggesting a possible association between isotretinoin and depr
ession include a temporal association between use of the drug and depressio
n, positive dechallenges (often with psychiatric treatment), positive recha
llenges, and possible biologic plausibility. Compared with all drugs in the
FDAs Adverse Event Reporting System database to June 2000, isotretinoin ra
nked within the top 10 for number of reports of depression and suicide atte
mpt.
Conclusion: The FDA has received reports of depression, suicidal ideation,
suicide attempt, and suicide in patients treated with isotretinoin. Additio
nal studies are needed to determine whether isotretinoin causes depression
and to identify susceptible persons. In the meantime, physicians are advise
d to inform patients prescribed isotretinoin (and parents, if appropriate)
of the possibility of development or worsening of depression. They should a
dvise patients (and parents) to immediately report mood swings and symptoms
suggestive of depression such as sadness, crying, loss of appetite, unusua
l fatigue, withdrawal, and inability to concentrate so that patients can be
promptly evaluated for appropriate treatment, including consideration of d
rug discontinuation and referral for psychiatric care.